Researchers found that elevated TGF beta levels lead to fascin overexpression, promoting tumor metastasis. High fascin expression is associated with poor prognosis.
Researchers developed a nanomedicine-based tool to target malignant melanoma, which showed promising results in preclinical studies. The system's ability to deliver targeted therapies with high affinity and selectivity holds great potential for improved diagnosis and therapy.
Researchers at Moffitt Cancer Center have found a way to 'expand' regulatory T-cell (Treg) cells to prevent graft-versus-host disease (GVHD), a serious risk in many cell transplants. The new method uses dendritic cells to activate Tregs, offering a potential breakthrough in preventing GVHD while sparing beneficial immune responses.
Researchers at Moffitt Cancer Center have discovered that hyperactivation of Akt and overexpression of IKBKE occur in 50 percent of human cancers. These findings suggest that targeting the inhibition of Akt may be an effective therapeutic strategy for treating breast cancer.
Research suggests earlier male circumcision can reduce HIV and HPV transmission rates in South Africa. The study found that high prevalence of HPV among HIV-infected men and their female partners limits the effectiveness of male circumcision as a prevention method.
Researchers found that free radical peroxynitrite is produced by myeloid cells in tumors and interferes with the immune system's ability to kill cancer cells. This mechanism may explain why some cancer immunotherapies fail to work, allowing tumors to evade immune detection.
Researchers discovered a chromatin insulator binding factor CTCF that blocks VEGF activation, regulating angiogenesis and cancer progression. This finding opens a window to manage angiogenesis and cancer using CTCF as a target.
Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance in ovarian cancer. The 'BCL2 antagonist of cell death' (BAD) pathway shows promise as a biomarker to identify patients with high-risk ovarian cancer and potentially reverse chemo-resistance.
Researchers at Moffitt Cancer Center have developed a monitoring technology that can provide a better understanding of drug resistance in multiple myeloma and assist in individualized patient treatments. The technique uses Liquid Chromatography Multiple Reaction Monitoring (LC-MRM) to quantify biomarkers of human disease.
The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy, which is considered the standard of care for advanced NSCLC. Studies have shown that low expression levels of ERCC1 are related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.
A Phase II trial of Revlimid found that over 75% of MDS patients reduced their need for transfusions, with two-thirds completely freed from transfusions. In 45% of cases, no detectable cancer was found after treatment.